MG
ADCT icon

Michael Gelband’s ADC Therapeutics ADCT Stock Holding History

Michael Gelband’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,280
Closed -$72.3K – 1522
2026
Q1 		$72.3K Sell
19,280
-37,503
-66% -$148K ﹤0.01% 1452
2025
Q4 		$200K Buy
56,783
+10,842
+24% +$44K ﹤0.01% 1387
2025
Q3 		$184K Buy
+45,941
New +$145K ﹤0.01% 1398
2022
Q4 		– Sell
-369,386
Closed -$1.78M – 1588
2022
Q3 		$1.78M Buy
369,386
+230,194
+165% +$1.67M 0.02% 845
2022
Q2 		$1.11M Buy
+139,192
New +$1.32M 0.01% 1034
2020
Q4 		– Sell
-81,624
Closed -$2.69M – 1905
2020
Q3 		$2.69M Buy
81,624
+64,199
+368% +$2.78M 0.05% 311
2020
Q2 		$816K Buy
+17,425
New +$661K 0.02% 846

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Michael Gelband's ADCT Position: Q2 2026 in Review

Michael Gelband sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 19,280 shares — an estimated $72.3K sold.

Michael Gelband first reported a position in ADCT in Q2 2020 and held it in 7 quarters. The position peaked at $2.69M in Q3 2020. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Michael Gelband reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 19,280 ADC Therapeutics shares in Q2 2026, an estimated $72.3K.
  • Michael Gelband first reported a position in ADC Therapeutics in Q2 2020 and held it in 7 quarters.
  • Michael Gelband's ADC Therapeutics position peaked at $2.69M in Q3 2020.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.